全文获取类型
收费全文 | 1168篇 |
免费 | 64篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 15篇 |
妇产科学 | 6篇 |
基础医学 | 224篇 |
口腔科学 | 5篇 |
临床医学 | 55篇 |
内科学 | 462篇 |
皮肤病学 | 19篇 |
神经病学 | 59篇 |
特种医学 | 33篇 |
外科学 | 154篇 |
综合类 | 4篇 |
预防医学 | 22篇 |
眼科学 | 2篇 |
药学 | 76篇 |
中国医学 | 1篇 |
肿瘤学 | 109篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 16篇 |
2020年 | 6篇 |
2019年 | 13篇 |
2018年 | 13篇 |
2017年 | 18篇 |
2016年 | 20篇 |
2015年 | 31篇 |
2014年 | 39篇 |
2013年 | 51篇 |
2012年 | 81篇 |
2011年 | 97篇 |
2010年 | 54篇 |
2009年 | 46篇 |
2008年 | 71篇 |
2007年 | 91篇 |
2006年 | 73篇 |
2005年 | 78篇 |
2004年 | 73篇 |
2003年 | 73篇 |
2002年 | 85篇 |
2001年 | 11篇 |
2000年 | 15篇 |
1999年 | 10篇 |
1998年 | 21篇 |
1997年 | 17篇 |
1996年 | 12篇 |
1995年 | 11篇 |
1994年 | 18篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1991年 | 6篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 6篇 |
1987年 | 10篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1978年 | 4篇 |
1977年 | 3篇 |
1973年 | 2篇 |
1969年 | 3篇 |
1968年 | 1篇 |
1967年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有1247条查询结果,搜索用时 968 毫秒
991.
Kazuki Sakatoku Yasunobu Takeoka Akiko Miura Taku Araki Yotaro Fujitani Ryosuke Yamamura Hirohisa Nakamae Kensuke Ohta Masayuki Hino 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(12):799-805
BackgroundWe investigated the prognostic effects of frailty and its association with comorbidity in patients with myelodysplastic syndrome (MDS).Patients and MethodsThis retrospective analysis included 118 consecutive patients diagnosed with MDS. Frailty was evaluated using the clinical frailty scale (CFS). Comorbidity was classified using the Charlson comorbidity index (CCI) and MDS comorbidity index (MDS-CI).ResultsOn multivariate analysis, CFS (≥ 5 vs. < 5; hazard ratio [HR], 3.37; P = .002), CCI (≥ 2 vs. < 2; HR, 2.59; P = .002), and Revised International Prognostic Scoring System (IPSS-R) category (HR, 2.1; P = .009) were independently predictive of overall survival (OS). One-year OS of patients with CFS ≥ 5 or CCI ≥ 2 were significantly worse compared with those with CFS < 5 or CCI < 2 (55% vs. 91%; P < .001; 46% vs. 91%; P < .001, respectively). OS was clearly stratified into 3 groups according to CFS (≥ 5 vs. < 5) and CCI (≥ 2 vs. < 2; P < .001). When comparing these 3 groups, the incidence of infection-related mortality progressively increased with CFS ≥ 5 and/or CCI ≥ 2 (P < .001). This effect was more obvious in patients with lower IPSS-R.ConclusionThe present study suggests frailty and comorbidity may be patient-related, independent predictive factors of poor prognosis. This could probably be attributed to increasing infection-related mortality with frailty and comorbidity. Combining the evaluation of frailty and comorbidity with IPSS-R might aid in more precise prediction of OS, especially in patients with low risk of MDS. 相似文献
992.
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study
下载免费PDF全文
![点击此处可从《Cancer science》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nobuaki Suzuki Shoichi Hazama Haruo Iguchi Kazuhiro Uesugi Hiroaki Tanaka Kosei Hirakawa Atsushi Aruga Takashi Hatori Hidenobu Ishizaki Yuzo Umeda Toshiyoshi Fujiwara Tetsuya Ikemoto Mitsuo Shimada Kazuhiko Yoshimatsu Ryoichi Shimizu Hiroto Hayashi Koichiro Sakata Hiroko Takenouchi Hiroto Matsui Yoshitaro Shindo Michihisa Iida Yasunobu Koki Hideki Arima Hiroyuki Furukawa Tomio Ueno Shigefumi Yoshino Yusuke Nakamura Masaaki Oka Hiroaki Nagano 《Cancer science》2017,108(1):73-80
We previously conducted a phase I clinical trial combining the HLA‐A*2402‐restricted KIF20A‐derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single‐armed, phase II trial using two antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2 in addition to the KIF20A peptide. We attempted to evaluate the clinical benefit of the cancer vaccination in combination with gemcitabine. Chemotherapy naïve PC patients were enrolled to evaluate primarily the 1‐year survival rate, and secondarily overall survival (OS), progression free survival (PFS), response rate (RR), disease control rate (DCR) and the peptide‐specific immune responses. All enrolled patients received therapy without the HLA‐A information, and the HLA genotypes were used for classification of the patients. Between June 2012 and May 2013, a total of 68 patients were enrolled. No severe systemic adverse effects of Grade 3 or higher related to these three peptides were observed. The 1‐year survival rates between the HLA‐A*2402‐matched and ‐unmatched groups were not significantly different. In the HLA‐A*2402 matched group, patients showing peptide‐specific CTL induction for KIF20A or VEGFR1 showed a better prognosis compared to those without such induction (P = 0.023, P = 0.009, respectively). In the HLA‐A*2402‐matched group, the patients who showed a strong injection site reaction had a better survival rate (P = 0.017) compared to those with a weak or no injection site reaction. This phase II study demonstrated that this therapeutic peptide cocktail might be effective in patients who demonstrate peptide‐specific immune reactions although predictive biomarkers are needed for patient selection in its further clinical application. 相似文献
993.
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
下载免费PDF全文
![点击此处可从《Cancer science》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dai Maruyama Kiyohiko Hatake Tomohiro Kinoshita Noriko Fukuhara Ilseung Choi Masafumi Taniwaki Kiyoshi Ando Yasuhito Terui Yusuke Higuchi Yasushi Onishi Yasunobu Abe Tsutomu Kobayashi Yukari Shirasugi Kensei Tobinai 《Cancer science》2017,108(5):1007-1012
Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in 17 Japanese patients with refractory/relapsed classical Hodgkin lymphoma previously treated with brentuximab vedotin. Sixteen patients were included in efficacy analyses and 17 in safety analyses. The primary endpoint was the centrally assessed objective response rate (ORR). The study was commenced in March 2015. We report data obtained at a cutoff of 16 March 2016, at which time 11 patients were still receiving nivolumab. The median (range) duration of treatment and follow‐up were 7.0 (1.4–10.6) months and 9.8 (6.0–11.1) months, respectively. All 17 patients had previously received brentuximab vedotin. The ORR was 81.3% (95% confidence interval [CI]: 54.4–96.0%; 13/16 patients), with complete remission and partial remission in 4 and 9 patients, respectively. The overall survival (OS) and progression‐free survival (PFS) rates at 6 months were 100 and 60.0% (95% CI: 31.8–79.7%), respectively; the median OS and PFS were not reached. The most common adverse events (AE) were pyrexia (41.2%), pruritus (35.3%), rash (35.3%) and hypothyroidism (29.4%). Four patients (23.5%) experienced grade 3 or 4 AE, but most AE were of grade 1 or 2. In conclusion, nivolumab is a potentially effective and tolerable treatment option for Japanese patients with relapsed/refractory classical Hodgkin lymphoma previously treated with brentuximab vedotin. 相似文献
994.
Hiroki Ishihara Tsunenori Kondo Kenji Omae Toshio Takagi Junpei Iizuka Hirohito Kobayashi Yasunobu Hashimoto Kazunari Tanabe 《International journal of clinical oncology / Japan Society of Clinical Oncology》2017,22(1):136-144
Background
We aimed to evaluate the effect of sarcopenia, a condition of low muscle mass, on the survival among patients who were undergoing radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UCUT).Methods
We retrospectively reviewed consecutive patients with UCUT (cT[any]N0M0) who underwent RNU between 2003 and 2013 at our department and its affiliated institutions. Preoperative computed tomography images were used to calculate each patient’s skeletal muscle index, an indicator of whole-body muscle mass. Sarcopenia was defined according to the sex-specific consensus definitions, based on the patient’s skeletal muscle and body mass indexes. We analyzed the relapse-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) after RNU to identify factors that predicted patient survival.Results
A total of 137 patients were included, and 90 patients (65.7 %) were diagnosed with sarcopenia. Compared to the non-sarcopenic patients, the sarcopenic patients had a significant inferior 5-year RFS (48.8 vs. 79.6 %, p = 0.0002), CSS (57.1 vs. 92.6 %, p < 0.0001), and OS (48.2 vs. 90.6 %, p < 0.0001). Multivariate analyses revealed that sarcopenia was an independent predictor of shorter RFS, CSS, and OS (all, p < 0.0001).Conclusions
Sarcopenia was an independent predictor of survival among patients with UCUT who were undergoing RNU.995.
Tsunenori Kondo Isao Hara Toshio Takagi Yoshiki Kodama Yasunobu Hashimoto Hirohito Kobayashi Junpei Iizuka Kenji Omae Kazuhiko Yoshida Kazunari Tanabe 《International journal of clinical oncology / Japan Society of Clinical Oncology》2017,22(1):145-152
Background
Our previous nonrandomized prospective study showed that template-based lymphadenectomy improved survival among patients with renal pelvic cancer but not among patients with ureteral cancer. However, regional node sites vary according to the tumor’s location in relation to the ureter. Therefore, this retrospective study examined the therapeutic role of lymphadenectomy for ureteral cancer according to tumor location.Methods
Between January 1988 and September 2015, we performed nephroureterectomy for 154 patients with nonmetastatic urothelial carcinoma of the ureter at two Japanese institutions. The tumors’ locations were classified as the lower ureter or the upper/middle ureter (before the cranial crossing of the common iliac artery). The appropriate regional nodes were identified based on our previous mapping study. Dissection was classified as complete lymphadenectomy (all regional sites were dissected), incomplete lymphadenectomy (not all sites were dissected), or no lymphadenectomy. We focused the analyses on patients with ≥pT2 disease to clarify the effect of the lymphadenectomy.Results
Among the 48 patients with upper/middle ureteral cancer, recurrence-free and cancer-specific survival were significantly higher in the complete lymphadenectomy group (vs. the incomplete or no lymphadenectomy groups). However, there were no differences in recurrence-free and cancer-specific survivals among the 56 patients with lower ureteral cancer. In the patients with upper/middle ureteral cancer, multivariate analysis revealed that template-based lymphadenectomy was independently associated with a reduced risk of cancer-specific mortality.Conclusions
Template-based lymphadenectomy has a therapeutic benefit for treating patients with upper/middle ureteral cancer but not for treating patients with lower ureteral cancer.996.
Mekata Y Hayashi N Masuda Y Kashimura O Arai S Kawano Y 《Journal of nutritional science and vitaminology》2008,54(2):154-162
This study was undertaken to investigate the effects of isoenergetic and increased amounts of egg white protein one hour before a run on the changes in the post-exercise blood biochemistry and the rating of the perceived exertion (RPE). Twenty-four male distance runners were divided into four groups. Venous blood samples were collected at three time points: just before the experiment (Pre), just after a 12,000 m run (Post 0 h) and one hour after the run (Post 1 h). After the first blood sampling, each participant consumed one of the four isoenergetic supplements (86 kcal); 0 g, 5 g, 10 g, or 20 g of egg white protein. The blood glucose, free amino acid, and branched chain amino acid (BCAA) levels in the 0 g, 5 g, and 10 g protein groups were higher at Post 0 h than at Pre. The pre-exercise intake of the 20 g protein group showed the smallest changes in the blood biochemicals. The RPE scores were significantly higher at Post 0 h, and did not vary among the four protein groups. Accordingly, the pre-exercise carbohydrate intakes significantly altered the post-exercise blood biochemisty findings, but the pre-exercise protein intake did not. Furthermore, the changes in the RPE scores in our present study were not explained by changes in the serum free tryptophan or the BCAA levels, and an increased dietary intake of egg white protein might not prevent post-exercise increases in the RPE scores. 相似文献
997.
998.
Mikako Katagiri Masao Takahashi Kent Doi Masahiro Myojo Arihiro Kiyosue Jiro Ando Yasunobu Hirata Issei Komuro 《Heart and vessels》2016,31(10):1595-1602
Serum neutrophil gelatinase-associated lipocalin (NGAL) is recognized as a useful biomarker for acute kidney injury. Recently, elevated NGAL levels were reported in patients with heart failure and cardiac events, but the association between serum NGAL and severity of coronary artery disease (CAD) has not been investigated adequately. This study aimed to evaluate the association between serum NGAL concentration and CAD severity in patients without heart failure and chronic kidney disease. Two-hundred thirteen patients [mean age: 66.2 ± 9.2 (SD)] without heart failure and chronic kidney disease (estimated glomerular filtration rate >60 mL/min/1.73 m2) who underwent coronary angiography were retrospectively analyzed using the SYNTAX score. The mean concentration of serum NGAL was 134.3 ± 111.3 ng/mL. A statistically significant correlation was observed between serum NGAL levels and the SYNTAX score (R = 0.18, P = 0.0091). Multivariable analysis also showed elevated serum NGAL as an independent risk factor for a high SYNTAX score (P < 0.01). Moreover, we evaluated the association of serum NGAL and brain natriuretic peptide (BNP) with the SYNTAX score. Patients with high levels of serum NGAL (>100 ng/mL) and high levels of BNP (>25 pg/mL) had a higher SYNTAX score (low–low vs. high–high: 13.8 ± 13.4 vs. 20.8 ± 18.9, P < 0.05). Serum NGAL levels were positively and significantly associated with CAD severity, and the evaluation of both serum NGAL and BNP was useful for predicting CAD in patients without renal dysfunction and heart failure. Serum NGAL might be a biomarker for CAD severity. 相似文献
999.
1000.